Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892226 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL918642 | 0.80 | MMP1 (0.50) | ALDH1A1MAPK1SMN1; SMN2CYP3A4NPC1 | |
| SCHEMBL16892220 | 0.80 | SCN9A (0.55) | ALDH1A1MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7454611 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPK1SMN1; SMN2CYP3A4NPC1 | |
| SCHEMBL16892164 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPK1SMN1; SMN2CYP3A4NPC1 | |
| SCHEMBL7456542 | 0.77 | MAPK14 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL4985848 | 0.77 | OPRM1 (0.51) | SMN1; SMN2CYP3A4HTTMMP13HPGD | |
| SCHEMBL4987260 | 0.76 | SLC1A3 (0.46) | SCN9AMAOB | |
| SCHEMBL4995873 | 0.76 | NPC1 (0.51) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL4994474 | 0.76 | MAPK14 (0.52) | ALDH1A1MAPK1SMN1; SMN2CYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058550-A4 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-12-18 | — | — | EP | claimed |
| US-6281211-B1 | TREATING A DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2001-08-28 | — | — | US | claimed |
| EP-1058550-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-12-13 | — | — | EP | claimed |
| WO-1999039712-A9 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | COCENSYS INC (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999039712-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (BE) | 1999-08-12 | — | — | WO | claimed |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | PURDUE PHARMA L.P. (US) | 2008-12-25 | — | — | US | disclosed |
| US-7393872-B2 | Sodium channel blocker compositions and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-07-01 | — | — | US | disclosed |
| EP-1169060-B1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2005-08-31 | — | — | EP | disclosed |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| EP-1058550-A4 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| US-6281211-B1 | TREATING A DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2001-08-28 | — | — | US | disclosed |
| EP-1058550-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
| WO-1999039712-A9 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | COCENSYS INC (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999039712-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (BE) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | ALDH1A1 1502/4885MAPK1 3855/4885SMN1; SMN2 590/4885 |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | CACNA1B, CACNB2, CACNA1C | ALDH1A1 1502/4885MAPK1 3855/4885SMN1; SMN2 590/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | ALDH1A1 1502/4885MAPK1 3855/4885SMN1; SMN2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.